Stress-Activated Kinase Mitogen-Activated Kinase Kinase-7 Governs Epigenetics of Cardiac Repolarization for
Sanjoy K Chowdhury1, Wei Liu1, Min Zi1
1From Faculty of Biology, Medicine and Health (S.K.C., W.L., M.Z., Y.L., S.W., H.T., S.P., C.B.M., M.R.B., E.J.C., H.A.S., X.W.) and School of Physics and Astronomy (S.C., H.Z.), University of Manchester, United Kingdom; Atherosclerosis Research Centre, Nanjing Medical University, Jiangsu, China (Y.J.); Institute of Molecular Medicine, Peking University, Beijing, China (X.Z., R.X.); Case Cardiovascular Research Institute, Case Western Reserve University, Cleveland, OH (R.Z., X.L., M.K.J.); Department of Pharmacology, University of Oxford, United Kingdom (M.L.); and Department of Cardiology and Pneumology, University Medical Center Göttingen, Germany (L.C., K.G.).
Background:
Ventricular arrhythmia is a leading cause of cardiac mortality. Most antiarrhythmics present paradoxical proarrhythmic side effects, culminating in a greater risk of sudden death.
Methods:
We describe a new regulatory mechanism linking mitogen-activated kinase kinase-7 deficiency with increased arrhythmia vulnerability in hypertrophied and failing hearts using mouse models harboring mitogen-activated kinase kinase-7 knockout or overexpression. The human relevance of this arrhythmogenic mechanism is evaluated in human-induced pluripotent stem cell-derived cardiomyocytes. Therapeutic potentials by targeting this mechanism are explored in the mouse models and human-induced pluripotent stem cell-derived cardiomyocytes.
Results:
Mechanistically, hypertrophic stress dampens expression and phosphorylation of mitogen-activated kinase kinase-7. Such mitogen-activated kinase kinase-7 deficiency leaves histone deacetylase-2 unphosphorylated and filamin-A accumulated in the nucleus to form a complex with Krüppel-like factor-4. This complex leads to Krüppel-like factor-4 disassociation from the promoter regions of multiple key potassium channel genes (Kv4.2, KChIP2, Kv1.5, ERG1, and Kir6.2) and reduction of their transcript levels. Consequent repolarization delays result in ventricular arrhythmias. Therapeutically, targeting the repressive function of the Krüppel-like factor-4/histone deacetylase-2/filamin-A complex with the histone deacetylase-2 inhibitor valproic acid restores K+ channel expression and alleviates ventricular arrhythmias in pathologically remodeled hearts.
Conclusions:
Our findings unveil this new gene regulatory avenue as a new antiarrhythmic target where repurposing of the antiepileptic drug valproic acid as an antiarrhythmic is supported.
Insights
Mitogen-activated kinase kinase-7 deficiency increases ventricular arrhythmia risk by disrupting potassium channel gene expression. Targeting this pathway with valproic acid may offer a new antiarrhythmic therapy.
Area of Science:
- Cardiology
- Molecular Biology
- Genetics
Background:
- Ventricular arrhythmia is a major cause of cardiac death.
- Existing antiarrhythmics often have proarrhythmic side effects, increasing sudden death risk.
Purpose of the Study:
- To investigate a novel regulatory mechanism linking mitogen-activated kinase kinase-7 (MKK7) deficiency to arrhythmia vulnerability in heart failure.
- To explore therapeutic strategies targeting this mechanism.
Main Methods:
- Utilized mouse models with MKK7 knockout or overexpression to study arrhythmia mechanisms in hypertrophied and failing hearts.
- Evaluated the human relevance using human-induced pluripotent stem cell-derived cardiomyocytes.
- Tested therapeutic interventions in both mouse models and human cells.
Main Results:
- Hypertrophic stress reduces MKK7 expression and phosphorylation, leading to an unphosphorylated histone deacetylase-2 and nuclear accumulation of filamin-A.
- This complex disrupts Krüppel-like factor-4 binding to potassium channel gene promoters, reducing channel expression and causing repolarization delays.
- Valproic acid, a histone deacetylase-2 inhibitor, restored potassium channel expression and reduced ventricular arrhythmias in pathological hearts.
Conclusions:
- Identified a new gene regulatory pathway involving MKK7, HDAC2, FLNA, and KLF4 as a critical determinant of ventricular arrhythmia susceptibility.
- Repurposing valproic acid as an antiarrhythmic agent is supported by these findings for treating pathological ventricular arrhythmias.
Related Concept Videos
Electrophysiology of Normal Cardiac Rhythm
G-Protein Gated Ion Channels
Sensory...
MAPK Signaling Cascades
Mechanism of Cardiac Arrhythmias
Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
cAMP-dependent Protein Kinase Pathways


